ORIC Q1 2025 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$33M

Net Income

-$30M

EPS (Diluted)

$-0.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$243M

Total Liabilities

$23M

Stockholders' Equity

$220M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$261,000	+100.0%
Operating Income	-$33M	-$29M	-12.9%
Net Income	-$30M	-$25M	-20.0%